These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 11870528)
21. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach. Murthy V; Karmakar S; Carlton J; Joshi A; Krishnatry R; Prabhash K; Noronha V; Bakshi G; Prakash G; Pal M; Menon S; Agrawal A; Rangarajan V Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e315-e321. PubMed ID: 33608206 [TBL] [Abstract][Full Text] [Related]
22. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M; J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083 [TBL] [Abstract][Full Text] [Related]
23. Tumor markers and Dondi F; Albano D; Bertagna F; Giubbini R Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969 [TBL] [Abstract][Full Text] [Related]
24. FDG PET for detection and therapy control of metastatic germ cell tumor. Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460 [TBL] [Abstract][Full Text] [Related]
26. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605 [TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab. Lamonica D; Graf DA; Munteanu MC; Czuczman MS J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362 [TBL] [Abstract][Full Text] [Related]
28. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations]. Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517 [TBL] [Abstract][Full Text] [Related]
29. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. Pfannenberg AC; Oechsle K; Bokemeyer C; Kollmannsberger C; Dohmen BM; Bares R; Hartmann JT; Vonthein R; Claussen CD World J Urol; 2004 Jun; 22(2):132-9. PubMed ID: 14735310 [TBL] [Abstract][Full Text] [Related]
30. Use of Diffusion-Weighted Imaging and Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Guay C; Lépine M; Verreault J; Bénard F J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411 [TBL] [Abstract][Full Text] [Related]
33. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Johns Putra L; Lawrentschuk N; Ballok Z; Hannah A; Poon A; Tauro A; Davis ID; Hicks RJ; Bolton DM; Scott AM Urology; 2004 Dec; 64(6):1202-7. PubMed ID: 15596197 [TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279 [TBL] [Abstract][Full Text] [Related]
36. Role of Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903 [TBL] [Abstract][Full Text] [Related]
37. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting. Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532 [TBL] [Abstract][Full Text] [Related]
38. Complete Metabolic Response on Interim Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466 [TBL] [Abstract][Full Text] [Related]
39. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171 [TBL] [Abstract][Full Text] [Related]
40. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]